Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(14%)
Results Posted
50%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_4
1
14%
Ph phase_1
2
29%
Ph phase_2
4
57%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 41 (14.3%)

Trials by Status

active_not_recruiting114%
unknown114%
completed457%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_1

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT06342986
terminatedphase_2

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

NCT02188368
completedphase_2

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT00350181
completedphase_2

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

NCT02243371
completedphase_1

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

NCT01966289
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06342986Phase 1

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Active Not Recruiting
NCT02188368Phase 2

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Terminated
NCT00350181Phase 2

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Completed
NCT02243371Phase 2

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

Completed
NCT01966289Phase 1

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Completed
NCT02981524Phase 2

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

Completed
NCT02838992Phase 4

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7